Safety of a protocol for reduction of agalsidase beta infusion time in Fabry disease: An Italian multi-centre study
Open Access
- 23 December 2021
- journal article
- letter
- Published by Elsevier in Molecular Genetics and Metabolism Reports
- Vol. 30, 100838
Abstract
No abstract availableThis publication has 4 references indexed in Scilit:
- Reduction of agalsidase beta infusion time in patients with fabry disease: A case series report and suggested protocolMolecular Genetics and Metabolism Reports, 2021
- Stepwise shortening of agalsidase beta infusion duration in Fabry disease: Clinical experience with infusion rate escalation protocolMolecular Genetics & Genomic Medicine, 2021
- FAbry STabilization indEX (FASTEX): an innovative tool for the assessment of clinical stabilization in Fabry diseaseClinical Kidney Journal, 2016
- Anti-α-galactosidase A antibody response to agalsidase beta treatment: Data from the Fabry RegistryMolecular Genetics and Metabolism, 2012